Sandoz Group AG (LON:0SAN)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 24.73B +82.0% |
| Revenue (ttm) | 8.29B +7.4% |
| Net Income | 679.10M |
| EPS | 1.55 |
| Shares Out | n/a |
| PE Ratio | 36.42 |
| Forward PE | 18.77 |
| Dividend | 0.55 (0.92%) |
| Ex-Dividend Date | Apr 17, 2025 |
| Volume | 45,266 |
| Average Volume | 216,274 |
| Open | 61.00 |
| Previous Close | 60.57 |
| Day's Range | 59.96 - 61.00 |
| 52-Week Range | 26.99 - 72.69 |
| Beta | 0.33 |
| RSI | 43.47 |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million
Strides Pharma Science shares gained over 3% after the company announced a strategic acquisition aimed at expanding its footprint in the Sub-Saharan Africa (SSA) region. As of 9:38 AM, the…
Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million
Strides Pharma Science Limited has announced a strategic acquisition to bolster its presence in the Sub-Saharan Africa (SSA) region. The company, through its step-down subsidiary Strides Pharma Intern...
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strateg...
Drugmakers must face skincare drug price-fixing lawsuit, US judge rules
A federal judge on Friday said 36 drugmakers and executives must face nearly all claims in an antitrust lawsuit brought by most U.S. states, accusing them of conspiring to fix prices of 80 generic dru...
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
PRINCETON, N.J.--(BUSINESS WIRE)--Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, today announced the US launch of its generic iron sucrose injection following recent appro...
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
MEDIA RELEASE Sandoz signs 10-year virtual PPA with Elawan Energy for new 150 MW solar projects in Spain Will cover nearly 90% of electricity demand for European operations Concrete step to support gl...
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, t...
Sandoz targets 70% price cut for weight-loss drugs in Canada, FT reports
Swiss generic drug manufacturer Sandoz plans to introduce unbranded weight-loss drugs in Canada at up to a 70% discount compared to branded versions when patents begin expiring next year, CEO Richard ...
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-bin...
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap...
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence ...
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...